)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
MannKind
MannKind (MNKD) investor relations material
MannKind Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary10 Mar, 2026
Strategic focus and business evolution
Transitioned from a single-product company to a diversified portfolio, highlighted by the acquisition of scPharmaceuticals in Q4 and ongoing integration efforts.
Aims to accelerate growth beyond market expectations, with two FDA approvals and a phase II trial planned for the year.
Exclusive manufacturing rights for Tyvaso secured, shifting from backup to primary supplier, stabilizing collaboration revenue.
Revenue streams are diversifying, with a growing share under direct control and a focus on Afrezza, FUROSCIX, and the nintedanib program.
Portfolio growth is prioritized, with a laser focus on trial enrollments, product launches, and rapid execution.
Revenue outlook and growth levers
Collaboration and service revenue expected to remain stable, while variable revenue (royalties and direct sales) is increasing.
By Q4, products under direct control surpassed royalty streams, with expectations to reach 70% of revenue from these sources.
Double-digit growth anticipated for Tyvaso DPI royalties, with Afrezza and FUROSCIX positioned as key future drivers.
FUROSCIX projected to generate $110–$120 million in 2024, with upside potential from the auto-injector launch.
Increased field rep investment for FUROSCIX expected to yield revenue inflection in Q2, setting up for further growth in Q3 and Q4.
Product pipeline and market positioning
FUROSCIX targets both community physicians and hospitals, with significant market opportunity in reducing hospital stays for fluid overload.
Auto-injector launch could rapidly convert patients from the on-body infuser, with a significant reduction in COGS and improved margins.
Competitive landscape includes new inhaled diuretics; company is developing its own inhaled version to address evolving market needs.
Afrezza shifting from profitability to growth mode, leveraging recent pediatric data and label changes to target a larger market.
Pediatric launch for Afrezza expected to drive significant market share, with 10–20% penetration equating to $150–$300 million in revenue.
Impact of exclusive Tyvaso manufacturing status
Furoscix auto-injector COGS reduction potential
Clinical differentiation of inhaled nintedanib
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next MannKind earnings date
Barclays 28th Annual Global Healthcare Conference11 Mar, 2026
MannKind
Next MannKind earnings date
Barclays 28th Annual Global Healthcare Conference11 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage